EXCALIBER RRMM

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Iberdomide, Daratumumab and Dexamethasone VS Daratumumab, Bortezomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

What's the purpose of the trial?

The goal of this clinical trial is to find the optimal dose of investigational drug iberdomide in combination with daratumumab and dexamethasone, and to study whether investigational drug iberdomide works in treating relapsed or refractory multiple myeloma when combined with daratumumab and dexamethasone.

Trial status

Accepting patients

Phase
Phase 3
Enrollment
864
Last Updated
3 days ago
Am I Eligible

Participating Centers

There are 27 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Bortezomib
  • Daratumumab
  • Dexamethasone
  • Iberdomide

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Iberdomide + Daratumumab + Dexamethasone

Accepting patients

Daratumumab + Bortezomib + Dexamethasone

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.